Vancouver, Canada, July 13, 2012 -- Immune Network Ltd. (IMMFF), announces that Immunitorís CEO, Dr. Aldar Bourinbaiar, was invited to give a keynote lecture on the subject of tuberculosis immunotherapy.
Online PR News – 13-July-2012 – July 11, 2012 Vancouver, Canada – Vancouver, Canada -- Immune Network Ltd. (IMMFF), announces that Immunitor's CEO, Dr. Aldar Bourinbaiar, was invited to give a keynote lecture on the subject of tuberculosis immunotherapy. The talk "Immunotherapeutic approaches in TB therapy" was given at the 3rd Biannual International Conference "Current Advances in Microbiology and Immunology," held in Ulaanbaatar, Mongolia.
Globally AIDS, malaria and tuberculosis are most common causes of death in developing world, with 9.4 million new cases of TB and 1.7 million people dying each year. Current TB drugs are not fully effective, particularly against multi-drug resistant TB (MDR-TB) and TB with HIV. Strenuous and often-toxic treatment regimens lasting for up to two years are required. The WHO statistics indicate one third of the world's population is latently infected with Mycobacterium tuberculosis Ė the infectious pathogen that causes TB. However not everyone develops the active disease. The WHO estimates that between 2000 and 2020, nearly a billion new people will be infected, of which 200 million will develop the disease, and 35 million will die if there is no improvement in handling the infection. The emergence of drug-resistant TB and TB/HIV became of great concern to TB caregivers and policymakers. The MDR-TB is on the rise, reaching for example, 10% or more in Russia and China. This necessitates finding alternative means for TB treatment, particularly new immunomodulators and therapeutic vaccines. Despite increasing attention to TB immunotherapy, available intervention choices are limited.
Immunitor is the leading biotechnology company specialized in discovery and marketing immune therapies for TB and other diseases. The lecture summarized the results of recent clinical trials involving three newly developed adjunct immunotherapies for TB. Some of the studies were already published in peer-reviewed medical journals. These and new unpublished findings support the tantalizing possibility to cure TB in just one month. "Our Phase II results indicate that duration of conventional and drug-resistant TB therapy can be reduced to as little as one month and we will be starting Phase III clinical trial in near future," said Dr. Dmytro Butov, the Principal Investigator of Immunitor's clinical trials in Ukraine. He added: "Today, the world relies on 50-year old TB drugs, which are not satisfactory. Positive gains in the fight against TB, prior to 1990s, have been lost primarily due to expansion of drug-resistant TB and AIDS epidemic. So, the perspective is rather bleak. Even if new drugs are introduced tomorrow, resistant strains will emerge immediately as it happened in the past. Without immune intervention we may lose the battle."
Safe Harbor Statement
The information in this release, other than historical information, may be considered forward-looking statements. Projection and other forward-looking statements and management expectations regarding future events and/or financial performance of the Company -- although given in good faith -- are inherently uncertain and actual events and/or results may differ materially.
For more information visit Immunitor company's website